Supporting strategic fundamental research in life sciences through carefully selected projects from universities in the Wallonia-Brussels Federation, with a view to transforming their discoveries into industrial applications.
Decio Eizirik's team (WELBIO-ULB) demonstrates the dual role played by NLRC5 within beta cells in the early stages of the disease.
THERAtRAME SA, a new spin-off of the University of Liège and WELBIO, secures €4.5M seed financing to develop novel cancer medicines in the field of tRNA epitranscriptomics.
Vendredi 7 octobre prochain, de 12 à 14h
Aux Moulins de Beez (Namur)
➡ Infos et inscription ici
WELBIO supports excellence in strategic basic research in life sciences. This mission is carried out within the framework of the « Fonds de la Recherche Fondamentale Stratégique » (FRS-FNRS).
WELBIO regularly meets with WELBIO Investigators and TTO representatives to discuss scientific advances, identify intellectual property and facilitate the translation of discoveries into biotechnology applications.
The Bridge Fund is a funding instrument intended for WELBIO Investigators and designed to bridge the gap between early-stage intellectual property and the development of a competitive package for the next technology transfer step.
WELBIO has gradually built up valorization opportunities that are taking many forms including projects supported by Biowin and SPW Research, licensing agreements, industry partnerships, and spin-off creation.
